Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other ... Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Mehr anzeigen
– Late-Breaker Poster Presentation Highlights Favorable Safety & Tolerability of OLC – – Two Publications Recently Issued Featuring OLC and UNI-494 – LOS ALTOS, Calif., Oct. 28, 2024 (GLOBE...
LOS ALTOS, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease...
LOS ALTOS, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0762 | -9.31312637497 | 0.8182 | 0.83 | 0.742 | 1120338 | 0.79535149 | CS |
| 4 | 0.012 | 1.64383561644 | 0.73 | 0.8655 | 0.6201 | 1275616 | 0.74817418 | CS |
| 12 | 0.362 | 95.2631578947 | 0.38 | 0.8655 | 0.3705 | 1546970 | 0.5847138 | CS |
| 26 | 0.292 | 64.8888888889 | 0.45 | 0.8655 | 0.202 | 1980704 | 0.44603462 | CS |
| 52 | -0.133 | -15.2 | 0.875 | 1.818 | 0.202 | 1252130 | 0.54789892 | CS |
| 156 | -1.118 | -60.1075268817 | 1.86 | 2.87 | 0.202 | 1104198 | 1.19597475 | CS |
| 260 | -7.808 | -91.3216374269 | 8.55 | 8.73 | 0.202 | 1032271 | 1.40868293 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
